In this European Parliament expert briefing session supported by EUCOPE and Novartis Gene Therapies, Tim Wilsdon presents work CRA has conducted on behalf of Novartis, examining barriers and opportunities to maximize the value of cell and gene therapies for patients through early detection.
Tim discusses how clinical outcomes can be improved through using early diagnosis and screening programs, such as newborn screening, to detect disease earlier.
Beyond the direct benefits for patients of improving early diagnosis and screening, it also provides opportunities for savings and increased sustainability for health systems.
His presentation, “How can we maximize the value of cell and gene therapies through early detection?” and the accompanying webinar can be found here.
